Patents by Inventor Daniel Paul Becker

Daniel Paul Becker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CARBORANE HYDROXAMIC ACID MATRIX METALLOPROTEINASE INHIBITORS AND AGENTS FOR BORON NEUTRON CAPTURE THERAPY
    Publication number: 20240050571
    Abstract: Disclosed herein are novel carborane hydroxamic acid matrix metalloproteinase (“MMP”) inhibitors and agents bearing borane-containing moieties and methods for their use in treating or preventing a disease, such as cancer and rheumatoid arthritis. In particular, disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salt thereof: Formula (I) wherein the substituents are as described.
    Type: Application
    Filed: February 28, 2023
    Publication date: February 15, 2024
    Inventors: Daniel Paul Becker, Marlon Ray Lutz, JR.
  • Carborane hydroxamic acid matrix metalloproteinase inhibitors and agents for boron neutron capture therapy
    Patent number: 11590226
    Abstract: Disclosed herein are novel carborane hydroxamic acid matrix metalloproteinase (“MMP”) inhibitors and agents bearing borane-containing moieties and methods for their use in treating or preventing a disease, such as cancer and rheumatoid arthritis. In particular, disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salt thereof: Formula (I) wherein the substituents are as described.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: February 28, 2023
    Assignee: LOYOLA UNIVERSITY OF CHICAGO
    Inventors: Daniel Paul Becker, Marlon Ray Lutz, Jr.
  • CARBORANE HYDROXAMIC ACID MATRIX METALLOPROTEINASE AGENTS FOR BORON NEUTRON CAPTURE THERAPY
    Publication number: 20220227792
    Abstract: Disclosed herein are novel carborane hydroxamic acid matrix metalloproteinase (“MMP”) agents bearing borane-containing moieties and methods for their use in treating or preventing a disease, such as cancer and rheumatoid arthritis. In particular, disclosed herein are compounds of Formula (I) and (II) and pharmaceutically acceptable salt thereof: wherein the substituents are as described.
    Type: Application
    Filed: June 15, 2020
    Publication date: July 21, 2022
    Inventors: Daniel Paul Becker, Sebastian Flieger, Isaac Schwarz
  • CARBORANE HYDROXAMIC ACID MATRIX METALLOPROTEINASE INHIBITORS AND AGENTS FOR BORON NEUTRON CAPTURE THERAPY
    Publication number: 20210290763
    Abstract: Disclosed herein are novel carborane hydroxamic acid matrix metalloproteinase (“MMP”) inhibitors and agents bearing borane-containing moieties and methods for their use in treating or preventing a disease, such as cancer and rheumatoid arthritis. In particular, disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salt thereof: Formula (I) wherein the substituents are as described.
    Type: Application
    Filed: June 28, 2019
    Publication date: September 23, 2021
    Inventors: Daniel Paul Becker, Marlon Ray Lutz
  • Indoline sulfonamide inhibitors of DapE and NDM-1 and use of the same
    Patent number: 11021469
    Abstract: Indoline sulfonamide compounds that can inhibit DapE and/or bacterial metallo-?-lactamases (MBLs), such as NDM-1, are disclosed. Also disclosed are methods of treating an individual suffering from a bacterial infection using the indoline sulfonamide compounds disclosed herein.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: June 1, 2021
    Assignees: LOYOLA UNIVERSITY OF CHICAGO, Board of Regents, The University of Texas System
    Inventors: Daniel Paul Becker, Tahirah K. Heath, Cory Reidl, Walter Fast
  • Indoline and tetrahydroquinoline sulfonyl inhibitors of dimetalloenzymes and use of the same
    Patent number: 10626087
    Abstract: Indoline and tetrahydroquinoline sulfonyl compounds that can inhibit DapE and/or bacterial metallo-?-lactamases (“MBLs”), such as NDM-1 are disclosed. Also disclosed are methods of treating an individual suffering from a bacterial infection using the compounds disclosed herein.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: April 21, 2020
    Assignees: LOYOLA UNIVERSITY OF CHICAGO, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Daniel Paul Becker, Cory Reidl, Maxwell Moore, Tahirah K. Heath, Walter Fast
  • INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME
    Publication number: 20190337931
    Abstract: Indoline sulfonamide compounds that can inhibit DapE and/or bacterial metallo-?-lactamases (MBLs), such as NDM-1, are disclosed. Also disclosed are methods of treating an individual suffering from a bacterial infection using the indoline sulfonamide compounds disclosed herein.
    Type: Application
    Filed: July 17, 2019
    Publication date: November 7, 2019
    Inventors: Daniel Paul Becker, Tahirah K. Heath, Cory Reidl, Walter Fast
  • Indoline sulfonamide inhibitors of DapE and NDM-1 and use of the same
    Patent number: 10385040
    Abstract: Indoline sulfonamide compounds that can inhibit DapE and/or bacterial metallo-?-lactamases (MBLs), such as NDM-1, are disclosed. Also disclosed are methods of treating an individual suffering from a bacterial infection using the indoline sulfonamide compounds disclosed herein.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: August 20, 2019
    Assignees: LOYOLA UNIVERSITY OF CHICAGO, MARQUETTE UNIVERSITY
    Inventors: Daniel Paul Becker, Richard C. Holz, Tahirah K. Heath, Cory Reidl, Anna Starus
  • INDOLINE AND TETRAHYDROQUINOLINE SULFONYL INHIBITORS OF DIMETALLOENZYMES AND USE OF THE SAME
    Publication number: 20190084932
    Abstract: Indoline and tetrahydroquinoline sulfonyl compounds that can inhibit DapE and/or bacterial metallo-62 -lactamases (“MBLs”), such as NDM-1 are disclosed. Also disclosed are methods of treating an individual suffering from a bacterial infection using the compounds disclosed herein.
    Type: Application
    Filed: July 11, 2016
    Publication date: March 21, 2019
    Inventors: Daniel Paul Becker, Cory Reidl, Maxwell Moore, Tahirah K. Heath, Walter Fast
  • INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME
    Publication number: 20170226090
    Abstract: Indoline sulfonamide compounds that can inhibit DapE and/or bacterial metallo-?-lactamases (MBLs), such as NDM-1, are disclosed. Also disclosed are methods of treating an individual suffering from a bacterial infection using the indoline sulfonamide compounds disclosed herein.
    Type: Application
    Filed: August 12, 2015
    Publication date: August 10, 2017
    Inventors: Daniel Paul Becker, Richard C. Holz, Tahirah K. Heath, Cory Reidl, Anna Starus, Walter Fast
  • Process for the preparation of azanoradamantane benzamides
    Patent number: 5717098
    Abstract: A process for the preparation of a .gamma.-lactone of the formula ##STR1## which can be used to produce a single enantiomer of aminoazanoradamantane which is coupled to aromatic acid moieties to produce compounds useful as 5-HT agonists or antagonists.
    Type: Grant
    Filed: July 22, 1996
    Date of Patent: February 10, 1998
    Assignee: G. D. Searle & Co.
    Inventors: Daniel Paul Becker, Daniel Lee Flynn, Alan Edward Moormann, Clara Ines Villamil
  • Process for the preparation of azanoradamantane benzamides
    Patent number: 5650535
    Abstract: A process for the preparation of a .gamma.-lactone of the formula ##STR1## which can be used to produce a single enantiomer of aminoazanoradamantane which is coupled to aromatic acid moieties to produce compounds useful as 5-HT agonists or antagonists.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: July 22, 1997
    Assignee: G. D. Searle & Co.
    Inventors: Daniel Paul Becker, Daniel Lee Flynn, Alan Edward Moormann, Clara Ines Villamil